Search
Purple Biotech Ltd
PPBTAdd to Watchlist
1.680USD
-0.060-3.45%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
1.52MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-30The current earnings forecast score of Purple Biotech Ltd is 8.00, ranking 165 out of 387 in the Biotechnology & Medical Research industry. The average price target is 34.00, with a high of 34.00 and a low of 34.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
30.000
Target Price
+1624.14%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Purple Biotech Ltd
PPBT
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Purple Biotech Ltd's price target?
Analysts forecast that Purple Biotech Ltd's price target is USD 34.00, with the highest forecast at USD 34.00 and the lowest forecast at USD 34.00.
How have Purple Biotech LtdPPBT's recent earnings per share performed?
The market expectation was USD -0.01, while Purple Biotech LtdPPBT's earnings per share (EPS) for the previous quarter was USD -2.54. EPS for the next quarter is expected at USD -0.40.
What is the analyst rating for Purple Biotech Ltd?
Based on the ratings of Purple Biotech Ltd's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
